Press Releases |News

12/12/2019

CVS Health Launches Transform Oncology Care™ Program to Help Improve Patient Outcomes and Lower Overall Costs

CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care...

12/11/2019

Tempus Announces the Acquisition of AKESOgen

CHICAGO and ATLANTA, December 11, 2019 — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced the acquisition of AKESOgen, an industry-leading commercial laboratory facility and provider of genomics and clinical trial precision medicine services based in Atlanta. AKESOgen is an integrated...

10/29/2019

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board Of Directors

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a...

09/30/2019

Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types ana...

09/17/2019

Cardiology

Geisinger and Tempus Announce Collaboration to Develop Cardiology Diagnostic and Prognostic Tools Using Artificial Intelligence

Geisinger announced today a new multi-year partnership with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The collaboration aims to use the power of machine learning and artificial intelligence to build new precision medicine tools for cardiology that will enable...

09/10/2019

Genmab and Tempus Enter into Strategic Collaboration Agreement

Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The multi-year collaboration will combine Tempus’ sequencing capabilities and industry-leading platform of integrated clinical...

09/03/2019

Tempus Expands Its Management Team with the Appointment of Lauren Silvis as Senior Vice President of External Affairs

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today the appointment of Lauren Silvis as its Senior Vice President of External Affairs. Silvis will oversee regulatory, public policy and government affairs, operating from Tempus’ office to...

08/29/2019

Tempus Announces New Subscription Service for Pharma, Biotech and Academic Researchers

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today that it is providing its de-identified datasets via a data subscription, enabling researchers to leverage unique, longitudinally-updated clinical and molecular data at scale, which will help accelerate...

08/22/2019

Tempus Expands Leadership Team with the Appointment of Joel Dudley, PhD, as Senior Vice President of Research

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment of Joel Dudley, PhD, as its Senior Vice President of Research. In his role, Dr. Dudley is responsible for leading Tempus’s research and development efforts...

06/11/2019

Genomic Sequencing

Tempus and Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission...

NEWS

Press Releases

Media Coverage

Additional Partnerships